Literature DB >> 9824498

High-level production of alternatively spliced soluble interleukin-6 receptor in serum of patients with adult T-cell leukaemia/HTLV-I-associated myelopathy.

S Horiuchi1, W Ampofo, Y Koyanagi, A Yamashita, M Waki, A Matsumoto, M Yamamoto, N Yamamoto.   

Abstract

We have previously shown, using human T-cell lymphocytotrophic virus-I (HTLV-I)-infected cell lines, that soluble interleukin-6 receptor (sIL-6R) is generated through an alternative splicing mechanism. In this study, we examined human sera for the presence of alternatively spliced soluble IL-6R (AS-sIL-6R). We produced a monoclonal antibody (mAb) recognizing the unique sequence of AS-sIL-6R peptide, generated by an altered reading frame. We also made recombinant AS-sIL-6R protein in Spodoptera frugiperda-9 (Sf-9) cells carrying baculovirus, which encoded altered sIL-6R or conventional IL-6R cDNA. mAbs specifically recognized AS-sIL-6R, but not conventional IL-6R, as demonstrated by Western blot analyses, fluorescence-activated cell sorter, immunofluorescence analyses and enzyme-linked immunosorbent assay (ELISA). We adapted an ELISA system and used it for detection of altered sIL-6R in sera from 23 healthy persons, 12 patients with adult T-cell leukaemia (ATL) and 13 patients with HTLV-I-associated myelopathy (HAM). Serum levels of AS-sIL-6R were 6.4 or 6.1 times greater in ATL (28.7+/-20.4 ng/ml, P<0.0001) and in HAM patients (27.5+/-12.1 ng/ml, P<0.0001) than in healthy individuals (4.5+/-2.1 ng/ml). High levels of AS-sIL-6R were also observed in plasma from rheumatoid arthritis patients and in persons with elevated levels of alanine aminotransferase (ALT), antinuclear antibody (ANA), or alpha-fetoprotein (AFP). However, in human immunodeficiency virus-1 (HIV-1), hepatitis B virus (HBV) or hepatitis C virus (HCV)-infected individuals, AS-sIL-6R levels were not elevated. In this study, we confirmed that AS-sIL-6R is indeed present in human sera. These observations suggest that alternative splicing of IL-6R mRNA is of consequence in ATL, HAM and in some autoimmune diseases. The HTLV-I-infected T cells appeared to play an important role in AS-sIL-6R production.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9824498      PMCID: PMC1364401          DOI: 10.1046/j.1365-2567.1998.00622.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  25 in total

1.  The soluble form of the IL-6 receptor (sIL-6R alpha) is a potent growth factor for AIDS-associated Kaposi's sarcoma (KS) cells; the soluble form of gp130 is antagonistic for sIL-6R alpha-induced AIDS-KS cell growth.

Authors:  K Murakami-Mori; T Taga; T Kishimoto; S Nakamura
Journal:  Int Immunol       Date:  1996-04       Impact factor: 4.823

2.  Clinical significance of elevated soluble interleukin-6 receptor levels in the sera of patients with plasma cell dyscrasias.

Authors:  K Ohtani; H Ninomiya; Y Hasegawa; T Kobayashi; H Kojima; T Nagasawa; T Abe
Journal:  Br J Haematol       Date:  1995-09       Impact factor: 6.998

3.  Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis.

Authors:  F De Benedetti; M Massa; P Pignatti; S Albani; D Novick; A Martini
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

4.  Soluble interleukin-6 receptor strongly increases the production of acute-phase protein by hepatoma cells but exerts minimal changes on human primary hepatocytes.

Authors:  C Gabay; P Silacci; B Genin; G Mentha; C Le Coultre; P A Guerne
Journal:  Eur J Immunol       Date:  1995-08       Impact factor: 5.532

5.  The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site.

Authors:  J Müllberg; W Oberthür; F Lottspeich; E Mehl; E Dittrich; L Graeve; P C Heinrich; S Rose-John
Journal:  J Immunol       Date:  1994-05-15       Impact factor: 5.422

6.  Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism.

Authors:  S Horiuchi; Y Koyanagi; Y Zhou; H Miyamoto; Y Tanaka; M Waki; A Matsumoto; M Yamamoto; N Yamamoto
Journal:  Eur J Immunol       Date:  1994-08       Impact factor: 5.532

7.  Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice.

Authors:  H Hirota; K Yoshida; T Kishimoto; T Taga
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

8.  Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor.

Authors:  M Mihara; Y Moriya; T Kishimoto; Y Ohsugi
Journal:  Br J Rheumatol       Date:  1995-04

9.  Two distinct and independent sites on IL-6 trigger gp 130 dimer formation and signalling.

Authors:  G Paonessa; R Graziani; A De Serio; R Savino; L Ciapponi; A Lahm; A L Salvati; C Toniatti; G Ciliberto
Journal:  EMBO J       Date:  1995-05-01       Impact factor: 11.598

10.  Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors.

Authors:  N Udagawa; N Takahashi; T Katagiri; T Tamura; S Wada; D M Findlay; T J Martin; H Hirota; T Taga; T Kishimoto; T Suda
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

View more
  8 in total

1.  The response of interleukin-6 and soluble interleukin-6 receptor isoforms following intermittent high intensity and continuous moderate intensity cycling.

Authors:  Melanie Leggate; Mari A Nowell; Simon A Jones; Myra A Nimmo
Journal:  Cell Stress Chaperones       Date:  2010-04-16       Impact factor: 3.667

2.  Elevated maternal soluble Gp130 and IL-6 levels and reduced Gp130 and SOCS-3 expressions in women complicated with preeclampsia.

Authors:  Yuping Wang; David F Lewis; Yang Gu; Shuang Zhao; Lynn J Groome
Journal:  Hypertension       Date:  2010-12-20       Impact factor: 10.190

3.  Soluble IL-6 receptor in vitreous fluid of patients with proliferative diabetic retinopathy.

Authors:  Miwako Kawashima; Jun Shoji; Masami Nakajima; Yumi Kamura; Yukihiro Sato
Journal:  Jpn J Ophthalmol       Date:  2007-04-06       Impact factor: 2.447

4.  Serum exosomes of chronic gastritis patients infected with Helicobacter pylori mediate IL-1α expression via IL-6 trans-signalling in gastric epithelial cells.

Authors:  Y Chen; X Wang; Y Yu; Y Xiao; J Huang; Z Yao; X Chen; T Zhou; P Li; C Xu
Journal:  Clin Exp Immunol       Date:  2018-10-01       Impact factor: 4.330

5.  Analysis of the role of interleukin 6 receptor haplotypes in the regulation of circulating levels of inflammatory biomarkers and risk of coronary heart disease.

Authors:  Bruna Gigante; Rona J Strawbridge; Ilais Moreno Velasquez; Zahra Golabkesh; Angela Silveira; Anuj Goel; Damiano Baldassarre; Fabrizio Veglia; Elena Tremoli; Robert Clarke; Hugh Watkins; Anders Hamsten; Steve E Humphries; Ulf de Faire
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

Review 6.  Generation of Soluble Interleukin-11 and Interleukin-6 Receptors: A Crucial Function for Proteases during Inflammation.

Authors:  Juliane Lokau; Maria Agthe; Christoph Garbers
Journal:  Mediators Inflamm       Date:  2016-07-14       Impact factor: 4.711

7.  Proteolytic Origin of the Soluble Human IL-6R In Vivo and a Decisive Role of N-Glycosylation.

Authors:  Steffen Riethmueller; Prasath Somasundaram; Johanna C Ehlers; Chien-Wen Hung; Charlotte M Flynn; Juliane Lokau; Maria Agthe; Stefan Düsterhöft; Yijue Zhu; Joachim Grötzinger; Inken Lorenzen; Tomas Koudelka; Kosuke Yamamoto; Ute Pickhinke; Rielana Wichert; Christoph Becker-Pauly; Marisa Rädisch; Alexander Albrecht; Markus Hessefort; Dominik Stahnke; Carlo Unverzagt; Stefan Rose-John; Andreas Tholey; Christoph Garbers
Journal:  PLoS Biol       Date:  2017-01-06       Impact factor: 8.029

Review 8.  Role of IL-6 in the commitment of T cell subsets.

Authors:  Thomas Korn; Michael Hiltensperger
Journal:  Cytokine       Date:  2021-07-26       Impact factor: 3.861

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.